A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
Ritz
Eberhard
E
Division of Nephrology, Department of Internal Medicine, Ruperto Carola University of Heidelberg, Germany. prof.e.ritz@t-online.de
Dahlöf
Björn
B
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use; D049628:Body Size; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D008019:Life Style; D024821:Metabolic Syndrome / Q000150:complications* / Q000628:therapy*; D009765:Obesity; D017257:Ramipril / Q000494:pharmacology / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects; D018570:Risk Assessment; D012307:Risk Factors; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D017257:Ramipril; D000077333:Telmisartan